Cambium Bio (ASX:CMB) Price-to-Operating-Cash-Flow : (As of Jun. 16, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Price-to-Operating-Cash-Flow?

As of today (2024-06-16), Cambium Bio's share price is A$0.006. Cambium Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00. Hence, Cambium Bio's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Cambium Bio's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 10 years, Cambium Bio's highest Price-to-Operating-Cash-Flow Ratio was 11.00. The lowest was 0.38. And the median was 6.32.

ASX:CMB's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.42
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Cambium Bio's Cash Flow from Operations per share for the six months ended in Dec. 2023 was A$0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 34.10% per year.

During the past 10 years, Cambium Bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 34.10% per year. The lowest was -15.60% per year. And the median was 10.80% per year.

Cambium Bio Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Cambium Bio's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Price-to-Operating-Cash-Flow Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

9.25

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Cambium Bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Price-to-Operating-Cash-Flow falls into.

Cambium Bio Price-to-Operating-Cash-Flow Calculation

Cambium Bio's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.006	/	-0.001
	=

Cambium Bio's Share Price of today is A$0.006.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Cambium Bio Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines